Melanoma Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Melanoma Information Center has current, evidence-based information for you. Get the facts about melanoma prevention, early detection, treatment, and survivorship, and stay up to date with ongoing melanoma research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Melanoma Community is the leading Social Media Application for Melanoma patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
The immunotherapy may take the place of chemotherapy as second- and third-line treatment. COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma
The COMBI-v trial compared the combination of the BRAF inhibitor dabrafenib (Tafinlar) plus the MEK inhibitor Mekinist (trametinib) with Zelboraf (vemurafenib) BRAF/MEK Inhibitor Combination Impressive in Melanoma Trials
The combination therapy resulted in improved response to treatment, prolonged time to cancer progression, and a reduction in mortality.
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse... Caregivers
What is Caregiving and Who are Caregivers? Caregivers are individuals who provide...
Sean Swarner is a master of setting a goal and achieving it. So when he... Jack & Jill Late Stage Cancer Foundation
Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the... Moving Bodies, Changing Lives
Moving On Aerobics helps women regain joy of movement and physical fitness after...
Melanoma Clinical Trials
VicalLX01-315-02 – A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7 Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma
COGE1697 – Phase III Randomized Study of Four Weeks High Dose IFN 2b in Stage T3-T4 or N1 (microscopic) Melanoma
ECOGE1697 – Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2b No, T3a-bNo, T4a-b No, and T1-2, N1a, 2a (microscopic) Melanoma.